Skip to main content
SpringerLink
Log in

Phase 1 study of conatumumab, a pro-apoptotic death receptor 5 agonist antibody, in Japanese patients with advanced solid tumors

  • Original Article
  • Published:
Cancer Chemotherapy and Pharmacology Aims and scope Submit manuscript

Abstract

Purpose

Conatumumab is a fully human monoclonal agonist antibody against human death receptor 5 (DR5). The primary objectives of this phase 1 study were to assess the safety, tolerability, and pharmacokinetics (PK) of conatumumab in Japanese patients with advanced solid tumors.

Methods

This is an open-label ascending dose study with a starting dose level of 3 mg/kg. Subsequent doses of 10 and 20 mg/kg were planned. Six patients were enrolled into 1 of 3 dose cohorts (3, 10, or 20 mg/kg) of conatumumab administered intravenously once every 2 weeks as a single agent. No conatumumab was administered on day 43 to allow the assessment of terminal PK parameters. The primary endpoints were the incidence of dose-limiting toxicities (DLTs) and assessment of PK parameters of conatumumab.

Results

Eighteen patients received at least 1 dose of conatumumab. There were no DLTs observed as defined in the protocol. No patients had an adverse event leading to conatumumab discontinuation. Conatumumab demonstrated dose-linear kinetics. A best response of stable disease was reported in nine patients. Monocytes were found to express DR5 and showed a high degree of conatumumab receptor occupancy after treatment at all dose levels.

Conclusions

Conatumumab administered up to 20 mg/kg once every 2 weeks was well tolerated in Japanese patients with advanced solid tumors. Adverse events and PK in these patients were similar to those in the first in human (FIH) study.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

Similar content being viewed by others

References

  1. Pitti RM, Marsters SA, Rupper S et al (1996) Induction of apoptosis by Apo-2 ligand, a new member of the tumor necrosis factor cytokine family. J Biol Chem 271:12687–12690

    Article  PubMed  CAS  Google Scholar 

  2. Wiley SR, Schooley K, Smolak PJ et al (1995) Identification and characterization of a new member of the TNF family that induces apoptosis. Immunity 3:673–682

    Article  PubMed  CAS  Google Scholar 

  3. Kelly S, Ashkenazi A (2004) Targeting death receptors in cancer with Apo2L/TRAIL. Curr Opin Pharmacol 4:333–339

    Article  Google Scholar 

  4. Fesik SW (2005) Promoting apoptosis as a strategy for cancer drug discovery. Nat Rev Can 5:876–885

    Article  CAS  Google Scholar 

  5. DeRosier LC, Vickers SM, Zinn KR et al (2007) TRA-8 anti-DR5 monoclonal antibody and gemcitabine induce apoptosis and inhibit radiologically validated orthotropic pancreatic tumor growth. Mol Cancer Ther 6(12 pt1):3198–3207

    Article  PubMed  CAS  Google Scholar 

  6. DeRosier LC, Huang ZQ, Sellers JC et al (2006) Treatment with gemcitabine and TRA-8 anti-death receptor-5 mAb reduces pancreatic adenocarcinoma cell viability in vitro and growth in vivo. J Gastrointest Surg 10:1291–1300

    Article  PubMed  Google Scholar 

  7. Ibrahim SM, Ringel J, Schmidt C et al (2001) Pancreatic adenocarcinoma cell lines show variable susceptibility to TRAIL-mediated cell death. Pancreas 23:72–79

    Article  PubMed  CAS  Google Scholar 

  8. Xu ZW, Kleeff J, Friess H et al (2003) Synergistic cytotoxic effect of TRAIL and gemcitabine in pancreatic cancer cells. Anticancer Res 23:251–258

    PubMed  CAS  Google Scholar 

  9. Hylander BL, Pitoniak R, Penetrante RB et al (2005) The anti-tumor effect of Apo2L/TRAIL on patient pancreatic adenocarcinomas grown as xenografts in SCID mice. J Transl Med 3:22

    Article  PubMed  Google Scholar 

  10. LoRusso P, Hong D, Heath E et al (2007) First-in-human study of AMG 655, a pro-apoptotic TRAIL receptor-2 agonist, in adult patients with advanced solid tumors. ASCO Meeting Abstracts 25:3534

    Google Scholar 

  11. Ashkenazi A (2002) Targeting death and decoy receptors of the tumor-necrosis factor superfamily. Nat Rev Cancer 2(6):420–430

    Article  PubMed  CAS  Google Scholar 

  12. Johnstone RW, Frew AJ, Smyth MJ et al (2008) The TRAIL apoptotic pathway in cancer onset, progression and therapy. Nat Rev Cancer 8:782–798

    Article  PubMed  CAS  Google Scholar 

  13. Ashkenazi A, Pai RC, Fong S et al (1999) Safety and antitumor activity of recombinant soluble Apo2 ligand. J Clin Invest 104:155–162

    Article  PubMed  CAS  Google Scholar 

  14. Kaplan-Lefko P, Bush T, Belmontes B et al (2008) AMG 655, a fully human agonistic antibody against death receptor 5, enhances the anti-tumor activity of gemcitabine in MiaPaCa2/T2, a pancreatic cancer model. AACR Meeting Abstracts 49:3999

    Google Scholar 

  15. Calogiuri G, Ventura MT, Mason L et al (2008) Hypersensitivity to last generation chimeric, umanized and human recombinant monoclonal antibodies for therapeutic use. Curr Pharmaceutical Design 14:2883–2891

    Article  CAS  Google Scholar 

  16. Camidge D, Herbst RS, Gordon M et al (2007) A phase I safety and pharmacokinetic study of Apomab, a human DR5 agonist antibody, in patients with advanced cancer. ASCO Meeting Abstracts 25:3582

    Google Scholar 

  17. Tolcher AW, Mita M, Meropol NJ et al (2007) Phase I pharmacokinetic and biologic correlative study of mapatumumab, a fully human monoclonal antibody with agonist activity to tumor necrosis factor-related apoptosis-inducing ligand receptor-1. J Clin Oncol 25:1390–1395

    Article  PubMed  CAS  Google Scholar 

  18. Plummer R, Attard G, Pacey S et al (2007) Phase 1 and pharmacokinetic study of lexatumumab in patients with advanced cancers. Clin Cancer Res 13:6187–6194

    Article  PubMed  CAS  Google Scholar 

  19. Patnaik A, Wakelee H, Mita M et al (2006) HGS-ETR2—A fully human monoclonal antibody to TRAIL-R2: results of a phase I trial in patients with advanced solid tumors. ASCO Meeting Abstracts 24:3012

    Google Scholar 

  20. Lobo ED, Hansen RJ, Balthasar JP (2004) Antibody pharmacokinetics and pharmacodynamics. J Pharmaceut Sci 93:2645–2668

    Article  CAS  Google Scholar 

  21. Griffith TS, Wiley SR, Kubin MZ et al (1999) Monocyte-mediated tumoricidal activity via the tumor necrosis factor-related cytokine, TRAIL. J Exp Med 189:1343–1353

    Article  PubMed  CAS  Google Scholar 

  22. Washburn B, Weigand MA, Grosse-Wilds A et al (2003) TNF related apoptosis-inducing ligand mediates tumoricidal activity of human monocytes stimulated by Newcastle disease virus. J Immunol 170:1814–1821

    PubMed  CAS  Google Scholar 

  23. Hayakawa Y, Screpanti V, Yagita H et al (2004) NK cell TRAIL eliminates immature dendritic cells in vivo and limits dendritic cell vaccination efficacy. J Immunol 172:123–129

    PubMed  CAS  Google Scholar 

  24. Wilson NS, Dixit V, Ashkenzi A et al (2009) Death receptor signal transducers: nodes of coordination in immune signaling networks. Nat Immunology 10(4):348–355

    Article  CAS  Google Scholar 

  25. Sheridan JP, Marsters SA, Pitti RM et al (1997) Control of TRAIL-induced apoptosis by a family of signaling and decoy receptors. Science 277:818–821

    Article  PubMed  CAS  Google Scholar 

  26. Walczak H, Miller RE, Ariail K et al (1999) Tumoricidal activity of tumor necrosis factor-related apoptosis-inducing ligand in vivo. Nat Med 5(2):157–163

    Article  PubMed  CAS  Google Scholar 

  27. Pollack IF, Eriff M, Ashkenazi A (2001) Direct stimulation of apoptotic signaling by soluble Apo2L/tumor necrosis factor-related apoptosis-inducing ligand leads to selective killing of glioma cells. Clin Cancer Res 7:1362–1369

    PubMed  CAS  Google Scholar 

  28. Lamhamedi-Cherradi SE, Zheng SJ, Maguschak KA et al (2003) Defective thymocyte apoptosis and accelerated autoimmune diseases in TRAIL−/− mice. Nat Immunol 4:255–260

    Article  PubMed  CAS  Google Scholar 

  29. Cretney E, Takeda K, Yagita H et al (2002) Increased susceptibility to tumor initiation and metastasis in TNF-related apoptosis-inducing ligand-deficient mice. J Immunol 168:1356–1361

    PubMed  CAS  Google Scholar 

  30. Diehl GE, Yue HH, Hsieh K et al (2004) TRAIL-R as a negative regulator of innate immune cell responses. Immunity 21:877–889

    Article  PubMed  CAS  Google Scholar 

  31. Pan Y, Xu R, Peach M, et al (2007) Application of pharmacodynamic assays in a phase Ia trial of Apo2L/TRAIL in patients with advanced tumors. ASCO Meeting Abstracts, 3535

Download references

Acknowledgments

We would like to thank Francesca Civoli and Steven J. Swanson for clinical immunology analysis and John Thomas for providing training at Mitsubishi Chemical Medience Cooperation (Tokyo, Japan) to evaluate receptor occupancy by flow cytometry. Takeda Bio Development Center Ltd., Tokyo, Japan.

Author information

Authors and Affiliations

  1. Gastrointestinal/Oncology Division, National Cancer Center Hospital East, 6-5-1, Kashiwanoha, Kashiwa, Chiba, 277-8577, Japan

    T. Doi, A. Ohtsu, N. Fuse & T. Yoshino

  2. Shizuoka Cancer Center, Nagaizumi, Japan

    H. Murakami, N. Yamamoto, N. Boku & Y. Onozawa

  3. Amgen Inc., Thousand Oaks, CA, USA

    C-P. Hsu, K. S. Gorski & G. Friberg

  4. Takeda Bio Development Center Ltd., Tokyo, Japan

    T. Kawaguchi & T. Sasaki

Authors
  1. T. Doi
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. H. Murakami
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. A. Ohtsu
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. N. Fuse
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. T. Yoshino
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. N. Yamamoto
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. N. Boku
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Y. Onozawa
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. C-P. Hsu
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. K. S. Gorski
    View author publications

    You can also search for this author in PubMed Google Scholar

  11. G. Friberg
    View author publications

    You can also search for this author in PubMed Google Scholar

  12. T. Kawaguchi
    View author publications

    You can also search for this author in PubMed Google Scholar

  13. T. Sasaki
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to T. Doi.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Doi, T., Murakami, H., Ohtsu, A. et al. Phase 1 study of conatumumab, a pro-apoptotic death receptor 5 agonist antibody, in Japanese patients with advanced solid tumors. Cancer Chemother Pharmacol 68, 733–741 (2011). https://doi.org/10.1007/s00280-010-1544-1

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00280-010-1544-1

Keywords

Search

Navigation